4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
OKYO Pharma Limited (OKYO) operates in the Biotechnology industry and is headquartered in London, United Kingdom with about 5 employees. Its market capitalization is roughly $85 million. In the fiscal year ended 2026-03-31, OKYO reported $0M in revenue and ($9M) in net income.
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($8M) | ($7M) | ($16M) | ($13M) | — |
| Net Income | ($9M) | ($5M) | ($17M) | ($13M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | $21M | $4M | $2M | $5M | — |
| Total Liabilities | $9M | $9M | $7M | $7M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OKYO viewer.
About TickerBase · Data methodology & sources · Privacy · Terms